NLRC5, a promising new entry in tumor immunology.

Détails

Ressource 1Télécharger: BIB_48FEA406CC22.P001.pdf (579.89 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_48FEA406CC22
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
NLRC5, a promising new entry in tumor immunology.
Périodique
Journal For Immunotherapy of Cancer
Auteur(s)
Chelbi S.T., Guarda G.
ISSN
2051-1426 (Electronic)
ISSN-L
2051-1426
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
4
Numéro
1
Pages
39
Langue
anglais
Résumé
The recent use of T cell-based cancer immunotherapies, such as adoptive T-cell transfer and checkpoint blockade, yields increasing clinical benefit to patients with different cancer types. However, decrease of MHC class I expression is a common mechanism transformed cells take advantage of to evade CD8(+) T cell-mediated antitumor responses, negatively impacting on the outcome of immunotherapies. Hence, there is an urgent need to develop novel approaches to overcome this limitation. NLRC5 has been recently described as a key transcriptional regulator controlling expression of MHC class I molecules. In this commentary, we summarize and put into perspective a study by Rodriguez and colleagues recently published in Oncoimmunology, addressing the role of NLRC5 in melanoma. The authors demonstrate that NLRC5 overexpression in B16 melanoma allows to recover MHC class I expression, rising tumor immunogenicity and counteracting immune evasion. Possible ways of manipulating NLRC5 activity in tumors will be discussed. Highlighting the therapeutic potential of modulating NLRC5 levels, this publication also encourages evaluation of NLRC5, and by extension MHC class I pathway, as clinical biomarker to select personalized immunotherapeutic strategies.
Pubmed
Web of science
Open Access
Oui
Création de la notice
01/09/2016 15:49
Dernière modification de la notice
20/08/2019 14:56
Données d'usage